Katie R. Ryan
Assistant Professor
Also affiliated: Cappagh National Orthopaedic Hospital (2013–2014); Mater Misericordiae University Hospital (2021); National Institute of Biomedical Innovation, Health and Nutrition (2017); MRC Laboratory for Molecular Cell Biology (2018); Winthrop Rockefeller Foundation (2020); University College London (2018); The University of Tokyo (2017); University of Birmingham (2012–2015)
Faculty Researcher
Biochemistry & Molecular Biology, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Katie R. Ryan's research focuses on understanding the molecular mechanisms that drive cancer progression and identifying potential therapeutic targets. Her work has investigated the role of specific signaling pathways, such as those involving rho GTP-binding proteins and rho-associated kinases, in cell movement and invasion, particularly in lung and breast cancers. Ryan has also explored inhibitors targeting oncoproteins like RET and TRKA, examining their potential as anti-cancer agents. Her publications include studies on small-molecule inhibitors and their clinical development, as well as research into novel regulators of cancer cell invasion and migration. She has a h-index of 10 with 28 publications and 376 citations. Ryan collaborates with several researchers at the University of Arkansas for Medical Sciences, including Noemi Garcia Garcia and Brendan Frett.
Metrics
- h-index: 10
- Publications: 28
- Citations: 401
Selected Publications
-
Rnd3 regulates lung cancer cell invasion and migration independently of ROCK1 signaling via alpha 5 integrin modulation (2026)
-
Abstract 2645: Rnd3 depletion in lung cancer cell lines decreases cell invasion and migration in a ROCK1 independent manner (2025)
-
Abstract 2649: Defining how Rnd3, a novel regulator of breast cancer invasion, affects the metastatic potential of triple-negative breast cancer (2025)
-
Long-read sequencing for brain tumors (2024)
-
Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors (2024)
-
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development (2021)
-
Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach (2021)
-
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns (2020)
-
Chromoplexy and Chromothripsis Are Important Prognostically in Myeloma and Deregulate Gene Function By a Range of Mechanisms (2019)
-
Microhomology-mediated end joining drives complex rearrangements and overexpression of <i>MYC</i> and <i>PVT1</i> in multiple myeloma (2019)
-
Microhomology-mediated end joining drives complex rearrangements and over-expression of <i>MYC</i> and <i>PVT1</i> in multiple myeloma (2019)
-
Global 3D-Epigenetic Dysregulation of Cyclin D1 and D2 Actively Controls Their Expression Pattern in Multiple Myeloma (2018)
Research Interests
Rho family GTPases act as ‘molecular switches’ and are master regulators of many aspects of cellular behavior including regulation of the actin cytoskeleton, gene expression, cell cycle, cell migration, and apoptosis. Many cellular processes regulated by Rho GTPases, are commonly dysregulated in cancer. Our laboratory focuses on the identification of molecular mechanisms and signaling pathways involved in Rho GTPase signaling. Rho family GTPases act as ‘molecular switches’ and are master regulators of many aspects of cellular behavior including regulation of the actin cytoskeleton, gene expression, cell cycle, cell migration, and apoptosis. Many cellular processes regulated by Rho GTPases, are commonly dysregulated in cancer. My work focuses on the role of Rho GTPases in cell migration and invasion in several in vitro cancer models including lung, breast, and skin cancer. We utilize molecular and cellular biology techniques as well as proteomic approaches to identify novel therapeutic targets of metastasis.
Grants & Funding
As listed on this researcher's institutional profile.
- Determining How Driver Mutations Affect the Metastatic Potential of Lung Cancer Using Cell-based Assays and a Proteomic Approach Barton Award Spring FY22 Ryan Principal Investigator
- Center for Studies of Host Response to Cancer Therapy NIH Co-Investigator
- Center for Molecular Interactions in Cancer (CMIC) NIH Co-Investigator
- A proteomics approach to determining how driver mutations effect the metastatic potential of lung cancer Seeds of Science Pilot Award UAMS Cancer Institute Principal Investigator
- Defining how Rnd3, a novel regulator of breast cancer invasion, affects the metastatic potential of breast cancer Arkansas Breast Cancer Research Program Principal Investigator
Collaboration Network
Top Collaborators
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Abstract 2649: Defining how Rnd3, a novel regulator of breast cancer invasion, affects the metastatic potential of triple-negative breast cancer
- Abstract 2645: Rnd3 depletion in lung cancer cell lines decreases cell invasion and migration in a ROCK1 independent manner
- Rnd3 regulates lung cancer cell invasion and migration independently of ROCK1 signaling via alpha 5 integrin modulation
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Abstract 2649: Defining how Rnd3, a novel regulator of breast cancer invasion, affects the metastatic potential of triple-negative breast cancer
- Abstract 2645: Rnd3 depletion in lung cancer cell lines decreases cell invasion and migration in a ROCK1 independent manner
- Rnd3 regulates lung cancer cell invasion and migration independently of ROCK1 signaling via alpha 5 integrin modulation
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Long-read sequencing for brain tumors
- Abstract 2645: Rnd3 depletion in lung cancer cell lines decreases cell invasion and migration in a ROCK1 independent manner
- Abstract 2649: Defining how Rnd3, a novel regulator of breast cancer invasion, affects the metastatic potential of triple-negative breast cancer
- Abstract 2645: Rnd3 depletion in lung cancer cell lines decreases cell invasion and migration in a ROCK1 independent manner
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Long-read sequencing for brain tumors
- Long-read sequencing for brain tumors
- Long-read sequencing for brain tumors
Similar Researchers
Based on overlapping research topics